# A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

> **NCT06887348** · — · RECRUITING · sponsor: **Replimune, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma
- Metastatic Melanoma
- Advanced Solid Tumor
- Hepatocellular Carcinoma

## Interventions

- **OTHER:** Observational study with no interventions

## Key facts

- **NCT ID:** NCT06887348
- **Lead sponsor:** Replimune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2030-12
- **Final completion:** 2035-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06887348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06887348, "A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06887348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*